1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Integrated BioPharma, Inc.

Integrated BioPharma, Inc.

INBP
Integrated BioPharma, Inc.US flagOther OTC
0.16
USD
-0.02
- -
4.97MMarket Cap
Integrated BioPharma, Inc.
INBP
(Other OTC)

Recent

price

0.16

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.99
1.96
1.74
1.6
1.6
1.78
2
2.22
2.07
1.73
1.78
2.14
1.89
1.69
1.67
1.79
1.56
Revenue per Share
-0.27
-0.11
-0.13
- -
0.01
0.03
0.05
0.11
0.03
0.06
0.14
0.27
0.13
- -
- -
0.03
-0.05
Basic EPS, GAAP
-0.01
- -
-0.04
-0.07
0.08
-0.02
-0.03
- -
0.04
- -
0.04
0.09
0.12
0.04
0.01
0.06
0.09
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-2.44
-2.51
-2.61
-2.6
-2.59
-2.55
-2.51
-2.4
-2.36
-1.67
-1.49
-1.21
-1.09
-1.08
-1.07
-1.04
-1.06
Book Value per Share
-0.35
-0.43
-0.55
-0.54
-0.52
-0.48
-0.41
-0.29
-0.25
0.07
0.21
0.48
0.63
0.63
0.64
0.67
0.61
Tangible Book Value per Share
20
21
21
21
21
21
21
21
21
29
30
30
30
30
30
30
31
Basic Weighted Avg Shares
20
41
37
34
34
37
42
47
44
50
53
64
56
51
50
54
48
Sales/Revenue/Turnover
-11.82
-0.89
-1.38
3.32
4.01
2.49
5.01
6.79
3.88
5.41
6.18
9.1
4.88
0.24
0.5
3.72
-2.58
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
1
1
1
Depreciation Expense
-6
-2
-3
- -
- -
1
1
2
1
2
4
8
4
- -
- -
1
-2
Net Income, GAAP
- -
- -
- -
15.45
40.45
15.42
19.43
- -
32.44
17.34
- -
- -
- -
134
58.21
60.81
167.16
Effective Tax Rate (%)
-27.45
-5.61
-7.41
0.28
0.39
1.96
2.27
5
1.55
3.38
7.78
12.61
6.82
-0.07
0.22
1.49
-3.43
Profit Margin (%)
-8
-11
-4
-2
-2
-3
- -
1
-4
2
3
9
11
12
12
15
12
Working Capital
- -
- -
9
10
9
9
10
9
4
6
4
2
1
2
1
- -
2
LT Debt
-6
-8
-10
-10
-10
-9
-8
-6
-5
2
6
14
19
19
19
20
19
Total Equity
- -
- -
- -
23.03
18.23
17.84
28.11
- -
12.27
18.54
- -
- -
- -
-0.19
0.49
3.74
6.69
Return on Invested Capital (%)
- -
- -
- -
-2.28
-1.76
-3.9
-4.48
- -
-3.69
-6.25
- -
- -
- -
0.16
-0.37
-2.66
-4.87
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
- -
- -
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
31
31
31
Market Capitalization
9
11
8

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
20
18
18
Cash, Cash Equivalents & STI
5
5
6
Accounts Receivable, Net
4
4
4
Inventories
10
8
8
Total Current Liabilities
5
4
6
Payables & Accruals
4
3
4
ST Debt
- -
- -
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.82%
35%
5.61%
Free Cash Flow
10.88%
83.71%
376.92%
Net Income, GAAP
53.02%
26.82%
621.43%
Sales/Revenue/Turnover
4.32%
1.27%
8.02%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
13
12
13
13
50
2025
14
13
14
14
54
2026
13
11
10
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
-0.01
0.01
- -
- -
2025
0.01
- -
0.02
-0.01
0.03
2026
- -
-0.02
-0.03
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Bio Green Med Solution, Inc. (BGMSP)
Greenwind Holdings Inc. (NEWG)
Satellos Bioscience Inc. (MSLE)
Gujarat Terce Laboratories Limited (GUJTERC.BO)
Hainan Haiyao Co., Ltd. (000566.SZ)
Cosmo Pharmaceuticals N.V. (CMOPF)
Business
Integrated BioPharma, Inc. Integrated BioPharma, Inc. (OTCQX:INBP) manufactures, distributes, markets and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. The company operates through two main segments: Contract Manufacturing, which produces vitamins and nutritional supplements for distributors, multilevel marketers, and specialized health-care providers; and Other Nutraceutical Businesses, which distributes branded products such as Peaceful Sleep and Wheatgrass through mass market, grocery, drug, and vitamin retailers, sells private label vitamins and supplements via the internet, provides warehousing and fulfillment services, and distributes fine natural botanicals including multi-minerals and raw materials for DSM Nutritional Products LLC. Integrated BioPharma, Inc. conducts its operations through subsidiaries including Manhattan Drug Company, Inc., AgroLabs, Inc., IHT Health Products, Inc., and MDC Warehousing and Distribution, Inc., doing business as Chem International Inc.; it serves the nutraceutical industry with high-quality, U.S.-manufactured products from its headquarters in Hillside, New Jersey, with a sales office in Florida. Founded in 1980 and formerly known as Integrated Health Technologies, Inc., the company maintains approximately 153 employees and focuses on compliance with industry standards in the consumer staples sector, specifically packaged foods and personal care products. Recent financial reporting includes results for the quarter and fiscal year ended June 30, 2025, reflecting ongoing operations in manufacturing and distribution without noted major acquisitions, partnerships, funding rounds, or strategic shifts in the past one to two years.

Company News

APIChatGPT

  • accessnewswire.com

    Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026

  • accessnewswire.com

    Integrated BioPharma Reports Results for Its Quarter Ended December 31, 2025

  • globenewswire.com

    Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions

  • accessnewswire.com

    Integrated BioPharma Reports Results for Its Quarter Ended September 30, 2025

  • accessnewswire.com

    Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2025

  • accessnewswire.com

    Integrated BioPharma Reports Results for its Quarter Ended March 31, 2025

  • accessnewswire.com

    Integrated BioPharma Reports Results for its Quarter Ended December 31, 2024

  • accesswire.com

    Integrated BioPharma Reports Results for its Quarter Ended September 30, 2024

  • accesswire.com

    Integrated BioPharma Reports Results for Its Quarter and Fiscal Year Ended June 30, 2024

  • accesswire.com

    Integrated BioPharma Reports Results for its Quarter Ended March 31, 2024

  • accesswire.com

    Integrated BioPharma Reports Results for its Quarter Ended December 31, 2023

  • accesswire.com

    Integrated BioPharma Reports Results for its Quarter Ended September 30, 2023

  • accesswire.com

    Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2023

  • prnewswire.com

    OTC Markets Group Welcomes Integrated BioPharma, Inc. to OTCQX

  • seekingalpha.com

    Integrated BioPharma: Strong Growth For Less Than A 5 P/E